Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Werte in diesem Artikel
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024.
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat on Wednesday, May 15, from 10:00 to 10:25 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found here.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507143335/en/
Ausgewählte Hebelprodukte auf Aurinia Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Aurinia Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Aurinia Pharmaceuticals Aktie News
Aurinia Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Aurinia Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 16.03.18 | Aurinia Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 08.02.18 | Aurinia Pharmaceuticals Outperform | RBC Capital Markets | |
| 30.10.17 | Aurinia Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 18.05.17 | Aurinia Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 11.04.17 | Aurinia Pharmaceuticals Overweight | Cantor Fitzgerald |